-+ 0.00%
-+ 0.00%
-+ 0.00%

OPKO HEALTH’S OPKO BIOLOGICS DOSES FIRST PARTICIPANT IN PHASE 1/2A TRIAL OF OPK-8801001 FOR ACROMEGALY

Reuters·10/27/2026 12:00:04

Please log in to view news